These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18165786

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P.
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 6. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF, GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 11. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C.
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK, Wittekind C, Niederwieser D.
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [Abstract] [Full Text] [Related]

  • 15. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ.
    Cancer; 2006 Oct 01; 107(7):1542-50. PubMed ID: 16948126
    [Abstract] [Full Text] [Related]

  • 16. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ, Lam MS, Rosenberg A.
    Ann Pharmacother; 2007 Oct 01; 41(10):1648-59. PubMed ID: 17848421
    [Abstract] [Full Text] [Related]

  • 17. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
    Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.
    Br J Haematol; 2006 Sep 01; 134(6):602-12. PubMed ID: 16889621
    [Abstract] [Full Text] [Related]

  • 18. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C, Kentos A, Remmelink M, Garbar C, Goldman S, Feremans W, Estenne M.
    Clin Transplant; 2006 Sep 01; 20(2):179-87. PubMed ID: 16640524
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 01; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 20. Failure of CHOP with rituximab for lymphomatoid granulomatosis.
    Oosting-Lenstra SF, van Marwijk Kooy M.
    Neth J Med; 2007 Dec 01; 65(11):442-7. PubMed ID: 18079567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.